

PRESS RELEASE  
19 April 2021



## **ERS Genomics and NUVISAN ICB sign CRISPR/Cas9 license agreement**

*CRISPR offerings to enhance NUVISAN's drug development service portfolio*

**Dublin, Ireland and Berlin, Germany, 19 April 2021:** ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and NUVISAN Innovation Campus Berlin (ICB) GmbH, a fully integrated contract research service provider for drug discovery and early development programs, today announced a non-exclusive license agreement granting NUVISAN ICB access to ERS Genomics' CRISPR/Cas9 patent portfolio.

NUVISAN ICB originated from a spin-out of the major pharma R&D functions of BAYER, which were acquired by NUVISAN in 2020. With its fully functional capabilities and capacities to support the entire drug discovery value chain, NUVISAN ICB offers integrated programs from target discovery to the clinic, including lead discovery, medicinal chemistry, pharmacology, drug metabolism and investigational toxicology. NUVISAN ICB's growing list of new clients comprises top pharmaceutical and biotechnology companies, as well as startups and venture capital groups.

ERS Genomics holds an exclusive worldwide license from co-founder and recent Nobel prize winner Dr. Emmanuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform.

**Eric Rhodes, CEO of ERS Genomics, said:** *"We are pleased to provide NUVISAN ICB access to this Nobel Prize winning technology, further expanding the reach of the important gene editing tool and enhancing NUVISAN's portfolio of service offering to organizations in the field of drug development."*

**Hans Lindner, Managing Director of NUVISAN ICB, commented:** *"CRISPR/Cas9 is revolutionizing drug development, and we are very pleased to now be able to add this capability to our service portfolio. The inclusion of CRISPR gene editing enables us to continue to meet our clients' needs, to help us advance their drug discovery and early development programs from the target to the patient."*

Financial details of the agreement are not disclosed.

**ENDS**



Eric Rhodes, CEO,  
ERS Genomics



Hans Lindner, Managing  
Director, NUVISAN ICB

**For high resolution images please contact Zyme Communications**

**Media contact:**

Katie Odgaard  
Zyme Communications  
Tel: +44(0)7787 502 947  
Email: [katie.odgaard@zymecommunications.com](mailto:katie.odgaard@zymecommunications.com)

**Contact NUVISAN:**

Elmar Rothenfusser  
Chief Marketing Officer  
Tel: +49 177 237 6100  
Email: [elmar.rothenfusser@nuvisan.com](mailto:elmar.rothenfusser@nuvisan.com)

*To opt-out from receiving press releases from Zyme Communications please email [info@zymecommunications.com](mailto:info@zymecommunications.com).*

*To view our privacy policy please [click here](#).*

**About ERS Genomics [www.ersgenomics.com](http://www.ersgenomics.com)**

ERS Genomics is a biotechnology company based in Dublin, Ireland. The company was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; companion animal and livestock health; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. For additional information please visit [www.ersgenomics.com](http://www.ersgenomics.com).

**About NUVISAN <https://www.nuvisan.com>**

The NUVISAN group is a Contract Research Organization (CRO) and Contract Manufacturing Organization (CDMO) with its headquarters in Neu-Ulm and six sites in Germany and France (Neu-Ulm, Berlin, Grafing, Gauting, Waltrop and Sophia-Antipolis) in addition to monitoring activities with offices in Argentina, Peru, Brazil as well as in the USA.

NUVISAN offers integrated and coupled services and solutions along the drug development value chain from target identification to the patient, with all supporting services (DMPK, GMP synthesis, formulation development and analysis, bioanalysis, Phase 1 CPU, clinical trial supplies and monitoring). Having a proven track record to include over 40 years of continuous service is a testimony to the operational excellence and the experience of our 1,000 highly qualified employees.

With a thorough service strategy plan, the NUVISAN group is today one of the fastest growing companies in the industry for the good of its partners and the patients they cure. NUVISAN prides itself through providing highly collaborative and strategic service solutions, from early biotech to the top 10 pharmaceutical companies and venture capital firms in the industry. For additional information please visit <https://www.nuvisan.com/>

NUVISAN INNOVATION CAMPUS BERLIN (NUVISAN ICB GmbH) is part of the NUVISAN Pharma Services Group. NUVISAN ICB is a newly founded dynamic contract research institute with about 450 employees, founded by the acquisition of a complete research unit from Bayer. Decades of experience and top-notch expertise in the field of drug discovery and early development combined with the spirit of a medium-sized, family-owned company create an innovative campus of excellence for early pharma research. For additional information please visit <https://www.InnovationCampusBerlin.com>